Anticorps Anti - CHEK1 (Ab - 317) produit dans un anticorps isolé rabbit affinity

Non disponible en dehors du Royaume-Uni et de l'Irlande

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Features and Benefits

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

Immunogen

Peptide sequence around aa. 315-319 (S-S-S-Q-P), according to the protein CHEK1.

Physical form

Solution in phosphate-buffered saline containing 0.02% sodium azide and 50% glycerol

Target description

Chek1 is a protein kinase that inhibits mitotic entry after DNA damage, required for the DNA damage checkpoint and is strongly similar to murine Chek1. Checkpoint pathways control the order and timing of cell cycle transitions and ensure that critical events, such as DNA replication and chromosome segregation, are completed with high fidelity. The mouse and human proteins share 90% sequence identity through the protein kinase domains. The sequence of the 476-amino acid human Chek1 protein is 29%, 40%, and 44% identical to those of the fission yeast Chek1, C. elegans Chek1, and Drosophila 'grapes' (Grp) proteins, respectively. Chek1 is expressed ubiquitously as an approximately 2.4-kb mRNA, with the most abundant expression in thymus, testis, small intestine, and colon. The protein has altered mobility when isolated from cells treated with ionizing radiation, indicating that Chek1 is modified in response to DNA damage. In vitro, Chek1 directly phosphorylates a regulator of CDC2 tyrosine phosphorylation, CDC25C. In response to DNA damage, Chek1 phosphorylates and inhibits CDC25C, thus preventing activation of the CDC2-Cyclin-B complex and mitotic entry.